Main Actions of Selumetinib
Inhibit Tumor Growth
By inhibiting vascular endothelial growth factor receptors, it reduces tumor angiogenesis and blocks tumor blood supply.
Inhibit Tumor Dissemination
Suppresses tyrosine kinase activity, preventing tumor cell invasion and migration.
Improve Symptoms
Can reduce tumor volume in certain cancers (e.g., renal cell carcinoma) and alleviate symptoms.
Adjuvant Therapy
Used in post‑operative patients with renal cell carcinoma to reduce the risk of recurrence.
Enhance Quality of Life
Prolongs survival time in patients with RET fusion‑positive non‑small cell lung cancer and thyroid cancer.
Important Precautions
Contraindicated Populations
Patients with a hypersensitivity to the active substance or any excipients, uncontrolled ocular diseases (e.g., retinal vein occlusion), or severe cardiac diseases should not use this medication.
Special Populations
Pregnancy
May cause fetal malformations; effective contraception is required until 1 week after discontinuation.
Lactation
May be secreted into breast milk; breastfeeding should be discontinued during treatment.
Pediatric Patients
Dosage must be strictly adjusted under medical guidance.
Drug Interactions
Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampicin) should be avoided, as these may alter plasma concentrations.
Monitoring and Follow‑Up
Regular monitoring of complete blood count, liver and renal function, cardiac function, and visual acuity is required during treatment.
Storage and Validity
Store below 25°C away from light and moisture.Keep capsules tightly sealed after opening.The usual validity period is 24 months; please refer to the packaging for specific details.
Efficacy and Limitations
Clinical studies have shown that approximately 60%–70% of patients with neurofibromatosis type 1 (NF1) experience tumor volume reduction (≥20%) following treatment; however, efficacy varies among individuals.The drug cannot cure the disease, and long‑term efficacy remains to be further observed.Treatment regimens should be adjusted based on imaging assessments (e.g., MRI) during therapy.
General Notice
The above content is for reference only. For detailed information, please refer to the official drug insert.Consult your attending physician before use and do not self‑administer medication blindly.
